Protalix Biotherapeutics Inc (PLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Protalix Biotherapeutics Inc (PLX) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.03 Million) by net assets ($48.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Protalix Biotherapeutics Inc (PLX) market capitalisation for the company's overall valuation and market capitalisation.
Protalix Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Protalix Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Protalix Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protalix Biotherapeutics Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Protalix Biotherapeutics Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Ruby Mills Limited
NSE:RUBYMILLS
|
-0.049x |
|
Hemisphere Energy Corporation
V:HME
|
0.193x |
|
Solocal Group SA
PA:LOCAL
|
-0.613x |
|
Atrium Therapeutics, Inc. Common Stock
NASDAQ:RNA
|
-0.093x |
|
CHC Healthcare Group
TW:4164
|
0.064x |
|
Ellington Residential Mortgage
NYSE:EARN
|
0.569x |
|
Sai Gon Cargo Service Corp
VN:SCS
|
0.091x |
|
Shaniv
TA:SHAN
|
0.112x |
Annual Cash Flow Conversion Efficiency for Protalix Biotherapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Protalix Biotherapeutics Inc from 1996 to 2025. View current stock price of Protalix Biotherapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $48.23 Million | $-11.99 Million | -0.249x | -223.88% |
| 2024-12-31 | $43.21 Million | $8.67 Million | 0.201x | +611.27% |
| 2023-12-31 | $33.57 Million | $-1.32 Million | -0.039x | -101.67% |
| 2022-12-31 | $-10.64 Million | $-25.00 Million | 2.350x | +37.89% |
| 2021-12-31 | $-6.04 Million | $-10.29 Million | 1.704x | +76.47% |
| 2020-12-31 | $-27.04 Million | $-26.11 Million | 0.966x | +250.76% |
| 2019-12-31 | $-70.32 Million | $-19.36 Million | 0.275x | +88.03% |
| 2018-12-31 | $-52.88 Million | $-7.74 Million | 0.146x | -54.16% |
| 2017-12-31 | $-31.29 Million | $-9.99 Million | 0.319x | -90.09% |
| 2016-12-31 | $-9.96 Million | $-32.10 Million | 3.224x | +244.34% |
| 2015-12-31 | $10.87 Million | $-24.28 Million | -2.233x | -524.10% |
| 2014-12-31 | $-55.60 Million | $-29.28 Million | 0.527x | -53.71% |
| 2013-12-31 | $-26.95 Million | $-30.65 Million | 1.138x | +701.39% |
| 2012-12-31 | $-3.36 Million | $635.00K | -0.189x | -120.93% |
| 2011-12-31 | $-26.08 Million | $-23.57 Million | 0.904x | -73.39% |
| 2010-12-31 | $-11.32 Million | $-38.46 Million | 3.397x | +21.38% |
| 2009-12-31 | $15.88 Million | $44.45 Million | 2.799x | +874.99% |
| 2008-12-31 | $44.35 Million | $-16.02 Million | -0.361x | -120.10% |
| 2007-12-31 | $63.69 Million | $-10.45 Million | -0.164x | +21.74% |
| 2006-12-31 | $24.28 Million | $-5.09 Million | -0.210x | -164.51% |
| 2005-12-31 | $914.43K | $-72.47K | -0.079x | +76.65% |
| 2004-12-31 | $495.36K | $-168.12K | -0.339x | -62.75% |
| 2003-12-31 | $655.43K | $-136.68K | -0.209x | -13.26% |
| 2002-12-31 | $796.15K | $-146.59K | -0.184x | +77.94% |
| 2001-12-31 | $945.91K | $-789.43K | -0.835x | -2011.77% |
| 2000-12-31 | $1.34 Million | $-53.11K | -0.040x | +95.54% |
| 1999-12-31 | $1.59 Million | $-1.41 Million | -0.886x | -226.92% |
| 1998-12-31 | $3.35 Million | $-909.52K | -0.271x | -- |
| 1997-12-31 | $0.00 | $-247.92K | x | -- |
| 1996-12-31 | $0.00 | $-40.57K | x | -- |
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more